Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$143.3K, compared with -$330.93K a year earlier. Trailing-twelve-month EBITDA was -$2.63M.
What to watch
Whether quarterly EBITDA holds near -$143.3K or moves back toward the trailing-twelve-month quarterly average of -$657.1K.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (2.82M) USD
- Year-over-year change
- -906.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.82M) | -906.3% |
| FY2024 | 2024-12-31 | (279.85K) | — |
EBITDA vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 EBITDA of -$2.63M is the 9th highest of the 10 companies compared; the peer median is -$1.11M.
- Its year-over-year change of -330.3% is the lowest of 4, against a peer median of -16.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.59M | -16.7% | — | — | |
| LTM Mar 2026 | $150K | +126.3% | — | — | |
OYSEOyster Enterprises II Acquisition Corp | LTM Mar 2026 | -$599.68K | — | — | — |
TACOUBerto Acquisition Corp. Unit | LTM Mar 2026 | -$1.11M | — | — | — |
| LTM Mar 2026 | -$1.11M | — | — | — | |
| LTM Mar 2026 | -$1.31M | — | — | — | |
| LTM Mar 2026 | -$1.37M | -251.8% | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | -$1.61M | — | — | — |
| LTM Mar 2026 | -$2.63M | -330.3% | — | — | |
| LTM Mar 2026 | -$3.06M | — | — | — | |
| Peer median (excluding DMAA) | -$1.11M | -16.7% | — | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 480 | 2.82M |
| Operating Expenses | 480 | 2.82M |
| Depreciation & Amortization | 480 | 0 |
| EBITDA | (279.85K) | (2.82M) |
| EBITDA Margin | — | — |
| Operating Income | (479) | (2.82M) |
| Operating Margin | — | — |
| Interest Income | 0 | 8.76M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 0 | 8.76M |
| Income Before Tax | (479) | 5.94M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | (479) | 5.94M |
| Net Margin | — | — |
| EPS (Basic) | (0.06) | 0.19 |
| EPS (Diluted) | (0.06) | 0.19 |
| Weighted Avg Shares | 8.57M | 21.01M |
| Weighted Avg Shares (Diluted) | 8.57M | 21.01M |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.